Bone Biologics secures exclusive DBM supply from MTF for rhNELL-1 spine fusion product

Bone Biologics Corp

Exclusive supply agreement with MTF Biologics for demineralized bone matrix (DBM) as carrier for rhNELL-1 bone graft substitute.
DBM will supply planned 30-patient pilot study and subsequent U.S. pivotal study in spine fusion.
Five-year term with extension option; targeting the $3 billion spine fusion market.
Also amended bylaws: stockholders with 15% voting power can call special meetings; exclusive Delaware forum for certain actions.

item 1.01 item 5.03 item 3.1 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.